INTRODUCTION
B-cell activating factor belonging to the tumor necrosis factor family (BAFF) is a fundamental survival factor for Bcells, and BAFF functionality is indispensable for B-cell maturation. BAFF is a trimeric membrane-bound or soluble factor, and is produced by monocytes, macrophages, neutrophils, and dendritic cells. 1, 2 Three receptors for BAFF have been determined : B-cell maturation antigen (BCMA), transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), and the BAFF-receptor (BAFF-R). All three receptors are expressed on B-cells, while TACI is also expressed on activated T-cells. Ligands of TACI and BCMA are not only BAFF but also a proliferation-inducing ligand (APRIL). However, the only ligand of BAFF-R is BAFF. TACI is known to negatively control B-cell homeostasis and T-cell independent immune responses as determined from studies on TACI-deficient mice. BCMA was recently reported to be essential for the survival of plasma cells. Thus, only BAFF-R is a significant receptor in the successful survival and maturation of B-cells. [1] [2] [3] [4] To the best of our knowledge, the distribution of BAFF-R in normal and malignant human lymphoid tissues has not been clarified yet.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group, with morphological subtypes that include centroblastic, immunoblastic, T-cell/ histiocyte-rich, and anaplastic, according to the WHO classification. 5 The cell origin of DLBCL is thought to be peripheral B-cells of either germinal center or post-germinal center cells, 6 and, interestingly, these subgroups are closely related to patient prognosis. 7 We tried to examine the relationship between BAFF-R and these subgroups of DLBCL with special reference to nodal and extranodal origins. DLBCLs were subclassified into GCB and non-GCB subgroups, which were determined by the expressions of three antigens : CD10, bcl-6, and MUM-1. CD10 is a key marker of germinal center cells, and is found in GCBtype DLBCL, Burkitt lymphomas, and follicular lymphoma. Bcl-6 is highly expressed in germinal center B-cells and tumors derived from germinal centers, such as follicular lymphoma. MUM-1 is a lymphoid-specific member of the interferon regulatory factor of transcription factors, and the protein is normally expressed in plasma cells and a minor subset of germinal center cells. Differences in BAFF-R expressions between sub-groupings of DLBCL, such as GCB versus non-GCB and nodal origins versus extranodal origins, have not yet been investigated in detail.
In the present study, we examined BAFF-R expression in not only B-cell lymphomas but also T-cell lymphomas and Hodgkin lymphomas, and the neoplastic cells of this latter group are also thought to be germinal center B-cells.
MATERIALS AND METHODS

Tissues
Formalin-fixed paraffin-embedded tissues of reactive hyperplasia of lymph nodes and malignant lymphomas were selected from our surgical pathologic file (Table 1) . Neoplastic lymphoid tissues from 140 patients with lymphomas were examined in the present study. 
Immunohistochemistry
Immunohistochemical analysis was performed by the avidin-biotin peroxidase complex method. In brief, deparaffinized 3-mm-thick tissue sections were placed in a microwave oven in 10 mM citrate buffer (pH6.0) for 10 min for antigen retrieval. After tissue sections were blocked with 0.3% hydrogen peroxidase in phosphate-buffered saline for 10 min at room temperature, each section was incubated overnight at 4°C with antibodies against CD10 (56C6, 1:50 ; Novocastra, Newcastle upon Tyne, UK), bcl-6 (PG-B6p, 1: 50 ; DAKO, Carpinteria, CA, USA), MUM-1 (MUM1p, 1: 40 ; DAKO), and Ki-67 (MIB-1, 1:1,000 ; Novocastra). After washing, samples were incubated with Envision+system labeled Polymer-HRP anti-mouse (DakoCytomation, Kyoto, Japan) for 30 min. Diaminobenzidine with H2O2 was used as the chromogen and hematoxylin as the nuclear counter stain. BAFF-R (8A7, 1:1 ; Kobata et al. 3 ) antibody stainings were performed using a Ventana benchmark machine (Ventana HX system, BenchMark ; Ventana Japan, Tokyo, Japan). Buffer CC2 (Ventana iVIEW DAB Universal Kit) was used for antigen retrieval. Primary antibodies were incubated for 30 min and the DAB detection kit (Ventana iVIEW DAB Universal Kit) was used for the stainings. Expressions of BAFF-R were examined immunohistochemically in all neoplastic lymphoid tissues, but expressions of CD10, bcl-6, MUM-1, and MIB-1 were examined in DLBCL only.
Statistical analysis
We used Fisher's exact test to identify correlations for categorical data. A p value of 0.05 or less was considered as statistically significant in all analyses.
RESULTS
Immunohistochemistry of non-neoplastic lymphoid tissue
Lymphocytes were positive for BAFF-R in the mantle zone, marginal zones of the secondary lymphoid follicles, some germinal center cells, and scattered interfollicular cells (Fig. 1) .
Immunohistochemistry of the neoplastic lymphoid tissue
The expression of BAFF-R on malignant lymphomas is summarized in Table 1 . BAFF-R expression was only found in B-cell lymphomas (60/120 sampled), but not in T/NK cell lymphomas (0/10) or in HLs (0/10).
For the B-cell lymphomas, BAFF-R 8 was detected in all of the examined cases of MCL (4/4) and CLL/SLL (4/4), and most of those of MZL (9/14) and FL (14/16) (Fig. 2) . Approximately half (44.3%) of DLBCLs (27/61) (15/32 : nodal, 12/29 : extranodal) were positive for BAFF-R (Fig. 3) . BAFF-R was detected predominantly on the lymphoid component of lymphoplasmacytic lymphomas but not on plasmacytic cells. Similarly, the malignant plasma cells of multiple myeloma (0/10) were negative for BAFF-R.
None of the B lymphoblastic lymphoma (0/5) was positive for BAFF-R. BL (0/4), and cases of NLPHL (0/4) were also negative for BAFF-R. Reed-Sternberg cells of classical HL were negative for BAFF-R. 9 
Immunohistochemistry of BAFF-R and germinal center markers in DLBCL
In nodal DLBCLs, BAFF-R was expressed in 15 of 32 (47%) cases, CD10 was expressed in 5 of 32 (16%), bcl-6 protein was expressed in 20 of 32 (63%), and MUM-1 was expressed in 21 of 32 (66%) ( Table 2 ). In extranodal DLBCLs, BAFF-R was expressed in 12 of 29 (41%) cases, CD10 was expressed in 8 of 29 (28%), bcl-6 protein was expressed in 16 of 29 (55%), and MUM-1 was expressed in 12 of 29 (41%) ( Table 3 ). In DLBCLs (nodal + extranodal), BAFF-R was expressed in 27 of 61 (44%) cases, CD10 was expressed in 13 of 61 (21%), bcl-6 protein was expressed in 36 of 61 (59%), and MUM-1 was expressed in 33 of 61 (54%) ( Table 4) .
According to Hans' criteria, 12 nodal DLBCLs were of GCB-type and 9 (75%) of these were positive for BAFF-R. Twenty nodal DLBDLs were of non-GCB-type and 6 (30%) of these were positive for BAFF-R (Table 2 ). In addition, 14 extranodal DLBCLs were of GCB-type and 8 (57%) of these were positive for BAFF-R. Fifteen extranodal DLBCLs were of non-GCB-type and 4 (27%) of these were positive for BAFF-R (Table 3) . Furthermore, 26 DLBCLs (nodal + extranodal) were of GCB-type and 17 (65%) of these were positive for BAFF-R. Thirty-five DLBCLs (nodal + extranodal) were of non-GCB-type and 10 (29%) of these were positive for BAFF-R (Table 4) .
BAFF-R expression and proliferation index assessed by MIB-1 immunostaining in DLBCL
BAFF-R expression was correlated with a low proliferation index assessed by MIB-1 immunostaining in nodal DLBCL. Among BAFF-R-positive samples (n = 15), the average MIB1 index was 37.3%, while it was 52.4% in BAFF-R-negative samples (n = 17) (p = 0.041) ( Table 5 ) (Fig. 4) . Among GCB-type DLBCL samples (n = 12), the average MIB1 index was 36.7%, while it was 50.5% in non-GCB samples (n = 20) (p = 0.070) ( Table 5) (Fig. 5) .
In contrast, in extranodal DLBCL, BAFF-R expression was not correlated with a low proliferation index assessed by MIB-1 immunostaining in DLBCL. Among BAFF-Rpositive samples (n = 12), the average MIB1 index was 62. 5%, while it was 52.9% in BAFF-R-negative samples (n = 17) ( Table 6 ). Among GCB-type DLBCL samples (n = 14), the average MIB1 index was 55.0%, while it was 58.7% in non-GCB samples (n = 15) ( Table 6 ).
DISCUSSION
In reactive lymph nodes, BAFF-R expression was de- DLBCL, diffuse large B-cell lymphoma ; BAFF-R, B-cell activating factor belonging to the tumor necrosis factor family receptor ; GCB, germinal center B-cell lymphoma ; non-GCB, non-germinal center B-cell lymphoma DLBCL, diffuse large B-cell lymphoma ; BAFF-R, B-cell activating factor belonging to the tumor necrosis factor family receptor ; GCB, germinal center B-cell lymphoma ; non-GCB, non-germinal center B-cell lymphoma DLBCL, diffuse large B-cell lymphoma ; BAFF-R, B-cell activating factor belonging to the tumor necrosis factor family receptor ; GCB, germinal center B-cell lymphoma ; non-GCB, non-germinal center B-cell lymphoma Table 5 . In germinal centers, BAFF-R expression was very weak or faint (Fig. 1) . BAFF-R expression exhibited similar patterns between non-neoplastic lymph node and malignant lymphomas. However, a difference is that FL expressed BAFF-R (Fig. 2) . This result is similar to the fact that bcl-2 expression is detected in FL. BAFF-R might have a similar mechanism to that of bcl-2. In BL, neither BAFF-R nor bcl-2 was detected. The reason for this is unclear. According to this finding, BAFF-R might not be expressed at the early stage of germinal centers. BAFF-R was shown to be required for B-cell maturation and survival, and BAFF-R expression was not observed in Tcell lymphoma or HL. 9 In B-cell lymphoma, BAFF-R was not detected at the immature stage of lymphoblastic lymphomas or the final differentiated stage of plasmacytic lymphomas. In contrast, BAFF-R was found on mature-type lymphomas such as CLL, MCL, FL, and DLBCL. These findings strongly suggest that BAFF-R plays roles in cellular survival and the differentiation of peripheral B-cells, which is related to its expression in non-neoplastic lymph nodes. The lack of BAFF-R on plasmacytic cells indicated that these cells are end-stage B-cells and thus require no differentiation. Furthermore, the lack of BAFF-R on HL may be related to their cellular origin. 9 In the present series, nodal DLBCL consisted of 12 cases of GCB type and 20 of non-GCB type. The rate of positivity for BAFF-R of the former group was significantly higher than that of the latter group (p = 0.017). Extranodal DLBCL consisted of 14 cases of GCB type and 15 of non-GCB type. The rate of positivity for BAFF-R of the former group was higher than that of the latter group, although the difference was not significant (p = 0.099). In DLBCL (nodal and extranodal), BAFF-R expression was significantly associated with GCBtype DLBCL (p = 0.004). These results show that BAFF-R expression in nodal DLBCL was associated with GCB-type DLBCL. GCB-type DLBCL is thought to originate from germinal centers, and it is known to at least be related to germinal centers, although it is a malignant tumor. BAFF-R was detected on most FLs (87.5%). It is of interest that GCBtype DLBCL showed germinal-center-related molecules by DNA microarray analyses, and there were similar findings from the point of view of BAFF-R.
Some studies have reported a good prognosis of GCBtype DLBCL. [10] [11] [12] We focused on the proliferation index (MIB-1 index) of DLBCL, and found that cases of nodal DLBCL that were BAFF-R-positive had a significantly lower proliferation index than those that were BAFF-R-negative. It has been reported that patients with a low proliferation index tend to show a better prognosis than those with a high proliferation index. 13 This is thought to be due to the fact that BAFF-R expression in nodal DLBCL is associated with GCB- In extranodal DLBCL, high BAFF-R expression was not correlated with a low proliferation index. This may indicate that the properties of DLBCL differ between organs. It has also been reported that many genes were found to be differentially expressed in extranodal DLBCL compared with those in nodal DLBCL. 14 The results of the relationship between BAFF-R and MIB-1 index were interesting : BAFF-R was rather strongly associated with low growth activity of GCBtype DLBCL of nodal origin but not with that of extranodal origin. The reason for this finding has not been clarified yet. However, nodal and extranodal lymphomas are quite different in some respects. The MALT lymphoma related to chronic inflammation is specific for extranodal sites, while follicular lymphoma is predominantly of nodal origin, with the exception of the duodenum. The proportions of GCB-versus non-GCB-type DLBCLs in extranodal organs are not uniform : the vast majority of gastric, breast, CNS, testicular, and adrenal DLBCLs are of non-GCB type, whereas thyroid ones are predominantly of GCB type. These findings suggest that the pathogenesis of lymphomas of extranodal sites is not the same as that of nodal ones. If this is the case, nodal and extranodal GCB-type DLBCLs might not be the same. As a matter of fact, although the patients with non-GCB-type DLBCL show poor prognosis in general, patients with gastric DLBCL show excellent prognosis, although most of them are of non-GCB type. BAFF-R is related to the cellular maturation of B-cells, and matured-differentiated cells show low mitotic activity, although the exact mechanisms behind this remain unclear.
In conclusion, BAFF-R was only found in some B-cell lymphomas, and was closely associated with the expression pattern in normal counterparts. BAFF-R was rather strongly associated with low growth activity of GCB-type DLBCL of nodal origin.
